http://www.fpnotebook.com/
Genital HerpesAka: Herpes Simplex Virus 2, Herpes Genitalis, HSV II
- See Also
- Oral Herpes
- Neonatal Herpes Simplex Virus
- Epidemiology
- Most common cause of ulcerative STD in United States
- Affects 10-30% of sexually active
- U.S. Prevalence: 30-45 Million
- U.S. Incidence: 300,000 new symptomatic cases yearly
- Not reportable
- Pathophysiology
- Cause of genital herpes
- HSV II: 80-90%
- HSV I: 10-20%
- Associated with stressors
- Virus remains latent in spinal nerve roots
- Primary Infection
- Systemic symptoms (Prodrome precedes lesions)
- Fever
- Headache
- Malaise
- Myalgias
- Lesions
- Lesion development
- Starts as shallow Vesicle
- Umbilicates with central depression
- Ulcerate early in course
- Crusts and then re-epitheliazes without scarring
- Multiple, grouped lesions are common and may coalesce
- Very painful!
- Present for 4-15 days
- Adenopathy
- Starts during second or third week of disease
- Usually bilateral inguinal adenopathy
- Slightly enlarged, mildly tender
- Course
- Viral shedding: 15-16 days
- Complete lesion healing: 19-21 days
- Complications
- Aseptic Meningitis
- Occurs in 15% with primary genital herpes
- Sacral radiculopathy syndrome
- Sacral anesthesia, Urinary Retention
- May last up to 8 weeks
- Extragenital lesions
- Autoinoculation of buttocks, hands, eyes
- Transverse myelitis
- Non-Primary Infection
- Prodrome (occurs in 50%, hours to days before lesions)
- Tingling
- Dysesthesia
- Numbness
- Adenopathy: slight, mildly tender
- Vessicles ulcerate and then crust
- Solitary or 3-4
- Enlarges over 3-4 days
- Peaks at 4-8 days
- Course
- Viral shedding during first 3-4 days
- Recurrence
- 5-8 episodes per year
- Diagnosis
- Sample collection
- Lance vessicle and place viral swab into fluid
- Viral culture of vesicular fluid
- Culture requires 2-3 days minimum, as long as 10 days
- Test Sensitivity: 75% (90% in primary episode)
- Best during vesicular or early ulcerative stage
- Not useful in lesions beyond 5 days old
- Differentiates HSV I from HSV II
- Polymerase chain reaction (PCR for HSV II)
- Test Sensitivity: 95%
- Provides more rapid results than viral culture
- Used in HSV Encephalitis diagnosis for rapid results
- HSV II direct immunofluorescence antigen detection
- Test Sensitivity: 80-90% of viral culture positive
- HSV serology (Glycoprotein G-specific HSV serology)
- Incidence of positives
- HSV: 90% of adults are positive
- HSV II: 30% of adults positive
- Indications
- Confirm HSV where history is questionable
- Recurrent lesions, but negative culture
- Management (Not Pregnant)
- General measures
- Keep infected area clean and dry
- Avoid secondary bacterial infections
- Avoid spread to uninvolved skin (autoinoculation)
- Wear comfortable clothing
- Loose fit
- Cotton underwear
- Apply an ice pack or baking soda compress to area
- Primary Infection (Initial episode)
- Outpatient
- Acyclovir
- 400 mg PO three times daily for 10 days OR
- 200 mg PO five times daily for 10 days
- Famciclovir 250 mg 3 times daily for 10 days
- Valacyclovir 1g PO twice daily for 10 days
- Shortens duration of pain, viral shedding
- Inpatient (Severe cases, hepatitis, CNS, pneumonitis)
- Acyclovir 5-10 mg/kg IV q8h for 2 to 7 days
- Convert to oral Acyclovir when able
- Recurrent (Start within 24 hours of first symptoms):
- Acyclovir
- 200 mg PO five times daily for 5 days or
- 400 mg PO three times daily for 5 days or
- 800 mg PO twice daily for 5 days or
- 800 mg PO three times daily for 2 days
- Two day regimen as effective as 5 day
- Wald (2002) Clin Infect Dis 34:944
- Famciclovir
- 125 mg orally twice daily for 5 days or
- 1 gram orally twice daily for 1 day
- Valacyclovir
- 500 mg orally twice daily for 3 days or
- 1 gram orally daily for 5 days
- Suppression/Prophylaxis
- Indications for suppression
- More than 6 episodes per year
- Consider for disabling episodes less often
- Acyclovir 400 mg orally twice daily for 12 months (Appears safe for up to 6 years)
- Prophylactic at stress times
- Decreases episodes from 11.4 to 1.8 per year
- Kaplowitz (1991) JAMA 265:747
- Famciclovir 250 mg orally twice daily
- Valacyclovir 500 mg orally daily
- Reduces HSV-2 transmission to partner by 50%
- Corey (2004) N Engl J Med 350:11
- Topical (oral agents are preferred)
- Penciclovir 1% cream ($20 for 2g tube)
- Efficacy
- Significant shortens duration of pain, healing
- (1997) Med Lett Drugs Ther 39(Issue 1003):57
- Dosing
- Start at first prodromal symptom
- Continue every 2 hours while awake for 4 days
- Viscous Lidocaine
- Applied to genital lesions
- Can give significant relief
- Management: Pregnancy (> 36 weeks gestation)
- Treat primary HSV II infections on protocol above
- Culture Cervix and lesion q3-5 days until negative
- Acyclovir if indicated
- See below for prevention of Neonatal HSV transmission
- Cesarean Section indications
- HSV II Culture positive
- All women with active HSV II lesions
- Management: Investigational
- L-lysine 1000 mg PO three times daily
- Aspirin 125 mg PO daily
- Local licorice root gels applied three times daily
- Lemon balm applied four times daily
- Zinc applied daily
- Aloe vera 0.5% applied three times daily
- Complications: Vertical transmission
- Neonatal Herpes Simplex Virus
- Prevention: Neonatal Herpes Simplex Virus transmission
- Prevent transmission from HSV positive partner
- Abstinence or Condom use during pregnancy
- Consider vaccine below
- Antiviral prophylaxis for HSV positive partner
- Avoid oral-genital contact if Oral HSV in partner
- HSV-2 Glycoprotein-D-Adjuvant Vaccine Indications
- HSV I and II negative women with positive partner
- Stanberry (2002) N Engl J Med 347:1652
- Identify HSV II risks in all pregnant women
- Personal history of HSV II
- Partners with HSV II
- Screen at first Prenatal Visit and perinatally
- Cesarean section for all women with active lesions
- Acyclovir indications (see dosing above)
- Third trimester prophylaxis if frequent outbreaks
- Any primary genital herpes outbreak during pregnancy
- All women with near-term or perinatal HSV II outbreak
- References
- Sheffield (2003) Obstet Gynecol 102:1396
- Prevention
- Avoid sexual contact during prodrome or when lesions
- Inform sexual partners of genital herpes
- Transmission can occur even when asymptomatic
- Condom use prevents transmission to women (not to men)
- Condom must cover active lesions
- Wald (2001) JAMA 285:3100
- Course
- Recurrence rate: Four episodes per year
- Factors predictive of more frequent recurrences
- Severe primary outbreak
- Male gender
- More frequent initially, decrease over time
- Exposure to provocative factors
- Fever
- Trauma
- Stressful situations
- Heat or cold extreme exposure
- Immunocompromised
- Menses
- Resources
- Herpes Resource Center: (919) 361-8488
- Herpes Web
- http://www.herpesweb.net
- CDC Herpes site
- http://www.cdc.gov/std/herpes/stdfact-herpes.htm
- References
- Beauman (2005) Am Fam Physician 72(8):1527
- Nadelman (2000) Postgrad Med 107(3):189
genital herpes (C0019342)
|
|---|
| Definition (MSH) | Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. |
| Definition (CSP) | infection caused by herpes simplex virus type 2 (HSV-2) that is usually transmitted by sexual contact; marked by recurrent attacks of painful eruptions on the skin and mucous membranes of the genital area. |
| Definition (NCI) | Herpes simplex infection on the genitals, most commonly caused by the herpes simplex-1 virus. |
| Concepts | Disease or Syndrome (T047)
|
| ICD9 | 054.1, 054.10 |
| English | Genital herpes, Genital Herpes Simplex, Genital herpes unspecified, HERPES GENITALIA, Herpes Genitalis, HERPES SIMPLEX VIRUS GENITAL INFECT, Herpes Simplex Virus Genital Infection, venereal herpes |
| Spanish | herpes genital, herpes genital no especificado, herpes simple genital, herpes simplex genital |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree